Insulin autoantibodies as determined by competitive radiobinding assay are positively correlated with impaired beta-cell function — The Ulm-Frankfurt population study by Yassin, Nuha et al.
Klin Wochenschr (1991) 69:736-741 
Originals 
Klinische 
Wochen- 
schrift 
9 Springer-Verlag 1991 
Insulin Autoantibodies as Determined by Competitive Radiobinding 
Assay are Positively Correlated with Impaired Beta-Cell Function- 
The Ulm-Frankfurt Population Study 
N. Yassin I, J. Seigler 1, M. Glfick 1, B.O. Boehm z, E. Heinze 3, E.F. Pfeiffer 1, and W.A. Scherbaum 1 
1 Abteilung Innere Medizin I, Universit/it Ulm, Ulm 
2 Abteilung Endokrinologie, Universit/it Frankfurt, Frankfurt 
3 Kinderklinik, Universit/it Ulm, Ulm 
Summary. Out of a random population of 4208 
non-diabetic pupils without a family history of 
Type I diabetes 44 (1.05%) individuals had islet 
cell antibody (ICA) levels greater or equal to 5 
Juvenile Diabetes Foundation (JDF) units. 39 of 
these ICA-positives could be repeatedly tested for 
circulating insulin autoantibodies (CIAA) using a 
competitive radiobinding assay. The results were 
compared with the insulin responses in the intrave- 
nous glucose tolerance tests (IVGTT) and with 
HLA types. Six pupils were positive for CIAA. 
All of them had complement-fixing ICA, and 5 
of them were HLA-DR4 positive. Three of the 6 
showed a first-phase insulin response below the 
first percentile of normal controls. Our data indi- 
cate that in population-based studies CIAA can 
be considered as a high risk marker for impaired 
beta-cell function in non-diabetic ICA-positive in- 
dividuals. 
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Type I diabetes as well as the prediabetic period 
are characterized by the presence in the serum of 
islet-specific autoantibodies and an impaired first- 
phase insulin response to intravenous glucose [16, 
18]. Insulin autoantibodies (IAA) were first de- 
scribed by Palmer et al. [13] in patients with newly 
diagnosed Type I (insulin-dependent) diabetes be- 
fore insulin treatment, and they were subsequently 
also identified in non-diabetic first-degree relatives 
Abbreviations: CF = complement-fixing; CIAA = circulating in- 
sulin autoantibodies; ELISA=enzyme-l inked immunosorbent 
assay; HLA = human leukocyte antigen; IAA = insulin autoan- 
tibodies; ICA = cytoplasmic islet cell antibodies; IVGTT = in- 
travenous glucose tolerance test; JDF=Juveni le  Diabetes 
Foundation; RIA = radioimmunoassay 
of such patients [1, 2, 7, 17]. Therefore, their possi- 
ble role as predictive markers for the future devel- 
opment of Type I diabetes has attracted much at- 
tention. 
Islet cell antibodies (ICA) are associated with 
newly diagnosed Type I diabetes and they have 
become indispensable tools for the initial screening 
to indicate the risk for the later development of
the disease. However, ICA may be transiently posi- 
tive and unrelated to diabetes [15], so that addi- 
tional parameters should be evaluated. Recently 
autoantibodies against proinsulin were described 
in diabetic patients and their relatives, but their 
predictive value for the development of Type I dia- 
betes is still unknown [11]. Eisenbarth [8] and At- 
kinson et al. [2] suggested that IAA determined 
by radioimmunoassay (RIA) may serve as high- 
risk markers in ICA-positive first-degree relatives, 
and time-dependent onset of Type I diabetes was 
also shown in life-table analyses, based on the level 
of IAA during the prediabetic period [23]. Accord- 
ing to the data thus far available from family stu- 
dies, IAA detected by ELISA seem to be unsuitable 
for such a prediction. 
Although 90% of the cases of Type I diabetes 
have no family history of this disease, data on IAA 
detected by competitive radiobinding assay 
(CIAA) have not been reported from population- 
based studies. We now studied CIAA in ICA posi- 
tive individuals from a random population in order 
to assess their correlation with beta-cell insuffi- 
ciency. 
Methods 
Study Population 
4208 pupils (2292 females, 1916 males, age range 
7-21 years; mean age 13.9 years) from 19 schools 
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in the Ulm/Alb-Donau County, Germany, were 
primarily investigated between July 1988 and July 
1989. The study was performed in accordance with 
the principles of the Declaration of Hetsinki. Writ- 
ten consent was given by the local Ethical Commit- 
tee, the Data Protection Council, individuals over 
18 years of age, and the parents of children studied. 
3 ml of blood were collected from the antecubital 
vein. The sera were given coded numbers and 
stored at -20  ~ C until they were used for further 
testing. 
Of the 4208 individuals initially screened, 44 
(1.04%) were ICA-positive. 39 of these ICA-posi- 
tive pupils were available for further testing after 
3 months, when CIAA were determined in fasting 
blood for the first time. Thus far, a follow up of 
15 months has been performed in most of them. 
Controls 
The sera of 100 ICA-negative pupils without a 
family history of diabetes were taken to evaluate 
normal values of CIAA. They were 45 females and 
55 males. The mean age of this group was 14 years, 
range 8-19 years. 39 age- and sex-matched ICA- 
negative class-mates of the ICA-positive individ- 
uals were taken as controls for CIAA determina- 
tion. As we were not allowed by our Ethical com- 
mittee to test for IVGTT's in normal children, 216 
healthy ICA negative adults were taken as controls 
for insulin secretion. 
193 randomly selected local control subjects (94 
female, 99 males) and 30 ICA-positive type I dia- 
betic individuals (15 females, 15 males) were taken 
as controls for HLA-DR typing. 1624 healthy 
blood donors were also HLA-typed to assess the 
frequencies of HLA-DR phenotypes. 
Primary Screening for Islet Cell Antibodies (ICA) 
Sera were tested by the standard indirect immuno- 
fluorescence test using 4 gm unfixed cryostat sec- 
tions of human pancreas as described [14]. Positive 
sera were then diluted until endpoint. In an inter- 
national quality control study, our laboratory 
achieved values of 100% for specificity, 75% for 
sensitivity and consistency and 87% for validity 
(Third IDW ICA Proficiency Program; Lab ID 
No. 116, WAS). The same pancreas and procedure 
were used in the survey here described. ICA test 
results were transferred to Juvenile Diabetes Foun- 
dation (JDF) units using the standard curve pro- 
vided for the workshop [6]. The lower limit of our 
assay is 5 JDF units. The tests were carried out 
in a "bl inded" manner by two investigators (G.T. 
and G.F.). In all ICA-positives, the sera were re- 
tested for ICA at intervals of 3 months. 
Complement-Fixing ICA ( CF-1CA ) 
ICA-positive sera were further tested for CF-ICA 
using an indirect immunofluorescence method, 
where serum of an ICA-negative healthy individual 
served as a source of complement [14]. This test 
was repeated every 3 months in all ICA-positive 
individuals. 
Blood Glucose Determination 
Blood glucose was tested in each of the sera with 
the hexokinase/G6P-DH method (Boehringer 
Mannheim, Germany) using an automatic Eppen- 
doff  analyzer. 
Intravenous Glucose Tolerance Test (IVGTT) 
ICA-positive individuals were tested by the IVGTT 
using the method described by Srikanta et al. [16]. 
After taking a 3 ml fasting blood sample (time 
point zero), 0.5 g glucose/kg body weight were ad- 
ministered intravenously over a period of 2 rain. 
Blood samples were then collected after 1, 3, 5, 
10, 20, and 30 min and stored at -70  ~ C until fur- 
ther testing. Insulin immunoreactivity was deter- 
mined by the CIS RIA-Kit (Griffe-sur-Yvette, 
France). The 1 + 3 minutes plasma insulin levels 
were calculated to indicate the early-phase insulin 
peak reflecting the secretory capacity of beta-cells. 
Values below 48 gU/ml, the first percentile of 216 
normal controls (92 females, 128 males, mean age 
29,5 years) were considered pathological. Individ- 
uals with a blunted first-phase insulin response 
were retested at intervals of 3 months, while all 
the others had a second IVGTT done after one 
year. 
Determination ofInsulin Autoantibodies ( CIAA ) 
The protocol used for the competitive RIA detect- 
ing specific insulin binding followed the method 
described by Vardi et al. [20]. Briefly, two sets of 
tubes were prepared with equal amounts of serum 
(150 gl/tube). Supraphysiologic concentrations of 
cold insulin (equivalent to 300 gU/ml serum) were 
added to one set of tubes and incubated at 4~ 
for at least one hour. Then physiologic oncentra- 
tions of xzsI-labeled insulin (equivalent to 10 taU/ 
ml serum) were added to both sets of tubes, fol- 
lowed by a 7 days-incubation period at 4 ~ C. 
Bound insulin was separated by polyethylene gly- 
col precipitation. Pellets were counted for 9 min 
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in the gamma-counter. The difference in percent 
binding with and without excess unlabeled insulin 
was translated into the absolute amount of labeled 
hormone displaced from the binding sites by com- 
petition with cold ligand (1 nU/ml=6.7x 
10-6 pM insulin precipitated). Participating at the 
First IAA Proficiency Test with this assay, our lab- 
oratory achieved a 100% specificity and con- 
sistency, 92% validity and 87% specificity (Lab 
ID No. 116, WAS). 
HLA Serology 
HLA-DR typing was performed by the standard 
two-colour fluorescence technique according to 
van Rood and coworkers [19]. Only antisera of 
the 10th International HLA Workshop were used. 
Results 
44 individuals out of a random population of 4208 
non-diabetic school-children without a family his- 
tory of Type I diabetes (1.05%) had ICA levels 
greater or equal to 10 JDF-units. 39 ICA-positive 
individuals could be tested for other parameters 
at follow-up investigations and 6 out of the 39 
(15.4%) were also positive for CF-ICA. 
33/39 showed no additional pathological pa- 
rameters during the whole follow-up period and 
they were therefore summarized in Table 1 (7-39). 
At initial testing for CIAA 5/39 (12.8%) ICA- 
positive pupils, but none of their age- and sex- 
matched class-mate controls were positive for 
CIAA. All 5 CIAA-positive individuals also had 
CF-ICA (Table 1). 3 months later one more pre- 
viously CIAA-negative pupil became positive (No. 
4 - Figure 1), so that all individuals who showed 
CF-ICA were CIAA positive at one occasion dur- 
ing the follow-up. 
HLA-DR3 and HLA-DR4 alleles were ob- 
served to be significantly increased in all ICA-posi- 
tive individuals when compared to controls (p < 
0.001). 5 of the 6 CF-ICA and CIAA-positive 
schoolchildren were HLA-DR4-positive, and 2 of 
the 5 were DR-4/3 heterozygous (Table 1). 
When the IVGTT was performed for the first 
time, 2/39 (5.1%) (No. 2 and No. 6 - Table 1) 
showed a first-phase insulin response below the 
first percentile of normal controls (<48 gU/ml). 
A third individual (No. 3 - Fig. 1) showed a 
blunted first-phase insulin response of 44 gU/ml 
3 months later. All 3 pupils with a pathological 
IVGTT were persistently ICA-positive. CF-ICA 
were persistently positive in 2 of them and they 
disappeared in one child during the follow-up (No. 
6 - Fig. 1). CIAA were persistently positive in all 
3 individuals over a period of 9-15 months. 
Proband No. 2 became insulin-dependent 16 
months after initial testing. This individual showed 
persistent ICA, CF-ICA and CIAA. CIAA had 
Table 1. Correlation of circulating insulin autoantibodies with the presence of complement-fixing islet cell antibodies and a blunted 
1 st-phase insulin response in ICA-positive pupils 
Pupil Age HLA-DR ICA CF-ICA CIAA IVGTT 1 + 3 min insulin 
(code No.) (years) type (JDF-units) (titre) (nU/ml) (gU/ml) 
initially after 12 months 
1 14 3.4 80 1/4 178 77 n.t. 
(8724882) 
2 15 1,2 60 1/2 101 42 <7 
(9905031) 
3 12 4,-- 80 1/2 49 85 44 
(8722424) 
4 13 3,4 10 1/2 10 58 n.t. 
(8724860) 
5 11 4,-- 80 1/2 241 205 152 
(8723637) 
6 8 4,w6 40 1/1 115 25 36 
(8722221) 
7-33 7-19 see text positive negative negative normal 
ICA=islet-cell antibodies, limit of detection is 5 JDF-units; CF-ICA=complement-fixing islet-cell antibodies; IAA=circulating 
insulin autoantibodies; _>45 nU/ml is taken as positive; IVGTT=intravenous glucose tolerance test, <48 uU/ml is below the 
first percentile of normals 
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Fig. 1. Results of follow-up investigations of islet-cell antibodies (ICA), complement-fixing ICA and circulating insulin autoantibo- 
dies in ICA-positive pupils. ICA: islet-cell antibodies, given in Juvenile Diabetes Foundation (JDF)-units. CF-ICA: complement- 
fixing ICA, given as titres. CIAA: circulating insulin autoantibodies measured by competitive radiobinding assay, results given 
in nU/ml 
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a mean of about 130 nU/ml over a period of 18 
months. 
Discussion 
Insulin autoantibodies detected by competitive ra- 
diobinding assay (CIAA) have been shown to be 
high risk markers for the future development of 
Type I diabetes in non-affected first-degree rela- 
tives of Type I diabetic patients [9]. We were here 
able to show for the first time that CIAA are highly 
correlated with beta-cell deficiency in non-diabetic 
individuals from a random population. Out of 39 
ICA-positive individuals aged 7-19 years, 6 had 
CIAA, and 3 of them had a first-phase insulin re- 
sponse below the first percentile of normals, which 
is thought to reflect a point of no return in the 
prediabetic state [17]. 
Since the mere presence of ICA in non-diabetic 
individuals is not necessarily followed by Type I 
diabetes, it is a major aim of ongoing studies to 
elucidate high-risk markers in ICA-positive indi- 
viduals. It was shown by Bottazzo's group that 
CF-ICA are correlated with a high risk for the 
later development of Type I diabetes in first-degree 
relatives of such patients [18]. During an eight-year 
follow-up period, 16 out of 719 individuals became 
diabetic, 13 of whom were CF-ICA positive. Also 
the data of Betterle et al. [5] in their ten-year fol- 
low-up study of non-diabetic patients with an or- 
gan-specific autoimmune disease other than Type 
I diabetes upport he predictive value of CF-ICA. 
CIAA were not determined in these studies. In our 
population-based investigation, 6 out of 4208 indi- 
viduals were positive for CF-ICA and 3 of them 
had an insulin response below the first percentile 
of normals. 
As not more than 10-15% of Type I diabetic 
patients have a family history of the disease, it 
is important o determine the prevalence and pre- 
dictive value of various risk markers in the random 
population. So far, two European population- 
based studies have been published. In the Spanish 
study an ELISA test was used for IAA determina- 
tion [3], while in the Finnish study IAA were not 
determined at all [10]. 
The dispute on the best method to apply for 
the detection of insulin autoantibodies (IAA) has 
been subject of several IAA standardization work- 
shops [12], which have shown that the results ob- 
tained by ELISAs do not correlate with the results 
obtained by radiobinding assays. In contrast o 
IAA determined by ELISA, CIAA are correlated 
with a high risk for the later development of Type 
I diabetes [22]. 
In the Caucasoid population, the HLA-DR3 
and DR4 alleles are strongly correlated with Type 
I diabetes [4]. In the whole cohort of our ICA- 
positive population, we found a significantly high- 
er number of subjects with the HLA-DR4 allele 
when compared to local controls. In untreated pa- 
tients, an association between insulin autoantibo- 
dies and HLA-DR3 or DR4 or both has been 
found by some authors [2, 9], but not by others 
[1, 21]. These differences may be due to the vari- 
ance of assays used for the detection of IAA. In 
our study with a 7-days incubation period in the 
competitive radiobinding assay, five out of six 
HLA-DR-typed CIAA-positive individuals re- 
vealed the DR4 allele, suggesting a positive corre- 
lation. 
Although the initial number of school-children 
screened is large, the positive cases found are few 
and the time of follow-up is relatively short to 
come to final conclusions. Yet, it already appears 
from our present data that the determination of 
CIAA in ICA positive non-diabetic individuals 
provides a valuable means to indicate impaired 
beta cell function which may allow further selec- 
tion of individuals at high risk for the future devel- 
opment of Type I diabetes among ICA-positive 
non-diabetic ndividuals in a random population. 
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